Delix Therapeutics, a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological conditions, today announced the appointment of Dr. Eliseo Salinas as Head of Research & Development. Dr. Salinas will support the continued acceleration and expansion of Delix’s world-class discovery, preclinical, and clinical pipeline of non-hallucinogenic, neuroplasticity-promoting psychoplastogens. “With a library containing thousands of psychedelic-inspired, non-hallucinogenic…